MX2021002484A - Amidas heterociclicas de 5 a 7 miembros como inhibidores de jak. - Google Patents

Amidas heterociclicas de 5 a 7 miembros como inhibidores de jak.

Info

Publication number
MX2021002484A
MX2021002484A MX2021002484A MX2021002484A MX2021002484A MX 2021002484 A MX2021002484 A MX 2021002484A MX 2021002484 A MX2021002484 A MX 2021002484A MX 2021002484 A MX2021002484 A MX 2021002484A MX 2021002484 A MX2021002484 A MX 2021002484A
Authority
MX
Mexico
Prior art keywords
membered heterocyclic
jak inhibitors
heterocyclic amides
compounds
amides
Prior art date
Application number
MX2021002484A
Other languages
English (en)
Spanish (es)
Inventor
Daniel D Long
Cameron Smith
Corbin Thompson
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2021002484A publication Critical patent/MX2021002484A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2021002484A 2018-09-04 2019-09-03 Amidas heterociclicas de 5 a 7 miembros como inhibidores de jak. MX2021002484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726583P 2018-09-04 2018-09-04
PCT/US2019/049342 WO2020051139A1 (en) 2018-09-04 2019-09-03 5 to 7 membered heterocyclic amides as jak inhibitors

Publications (1)

Publication Number Publication Date
MX2021002484A true MX2021002484A (es) 2021-05-12

Family

ID=68051893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002484A MX2021002484A (es) 2018-09-04 2019-09-03 Amidas heterociclicas de 5 a 7 miembros como inhibidores de jak.

Country Status (20)

Country Link
US (2) US10836763B2 (https=)
EP (1) EP3837010B1 (https=)
JP (1) JP7383696B2 (https=)
KR (1) KR20210056380A (https=)
CN (1) CN112703037B (https=)
AR (1) AR116114A1 (https=)
AU (1) AU2019335200A1 (https=)
BR (1) BR112021004063A2 (https=)
CL (1) CL2021000515A1 (https=)
CO (1) CO2021002976A2 (https=)
EA (1) EA202190686A1 (https=)
ES (1) ES2955717T3 (https=)
IL (1) IL281150B2 (https=)
MX (1) MX2021002484A (https=)
PH (1) PH12021550324A1 (https=)
SG (1) SG11202101751XA (https=)
TW (1) TWI793365B (https=)
UA (1) UA127328C2 (https=)
WO (1) WO2020051139A1 (https=)
ZA (1) ZA202100990B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004079A1 (en) 2014-06-30 2016-01-07 Black & Decker Inc. Battery pack for a cordless power tools
HK1252685A1 (zh) 2015-11-03 2019-05-31 Theravance Biopharma R&D Ip, Llc 用於治疗呼吸疾病的jak激酶抑制剂化合物
BR112019018648A2 (pt) 2017-03-09 2020-06-16 Theravance Biopharma R&D Ip, Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
PT3837258T (pt) 2018-09-04 2024-06-20 Theravance Biopharma R&D Ip Llc Amidas de dimetil amino azetidina como inibidores de jak
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
WO2020051139A1 (en) * 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as jak inhibitors
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2022081872A1 (en) * 2020-10-16 2022-04-21 Gb008, Inc. Janus kinase inhibitors
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
JP7644873B2 (ja) * 2021-12-17 2025-03-12 デウン ファーマシューティカル カンパニー リミテッド (2R,3S)-2-(3-(4,5-ジクロロ-1H-ベンゾ[d]イミダゾール-1-イル)プロピル)ピペリジン-3-オールの新規な酸付加塩および結晶形
WO2025172431A1 (en) * 2024-02-14 2025-08-21 Almirall, S.A. Stat6 inhibitors and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
JP4836788B2 (ja) 2003-07-23 2011-12-14 エグゼリクシス, インコーポレイテッド 未分化リンパ腫キナーゼ変調因子及びその使用法
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
EP2515655B1 (en) 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
MX368464B (es) 2013-12-05 2019-10-02 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
CR20160525A (es) 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
HK1252685A1 (zh) 2015-11-03 2019-05-31 Theravance Biopharma R&D Ip, Llc 用於治疗呼吸疾病的jak激酶抑制剂化合物
US10556901B2 (en) * 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
EP3712152B1 (en) * 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3484876A1 (en) * 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
BR112019018648A2 (pt) 2017-03-09 2020-06-16 Theravance Biopharma R&D Ip, Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
US10406148B2 (en) 2017-05-01 2019-09-10 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CN110603255B (zh) 2017-05-01 2023-02-10 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的结晶型式
WO2020051139A1 (en) * 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as jak inhibitors
PT3837258T (pt) 2018-09-04 2024-06-20 Theravance Biopharma R&D Ip Llc Amidas de dimetil amino azetidina como inibidores de jak
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
MX2021004582A (es) 2018-10-29 2021-06-15 Theravance Biopharma R&D Ip Llc Compuesto 2-azabiciclo hexano inhibidor de jak.
FI3932919T3 (fi) 2019-02-25 2024-08-30 Henan Medinno Pharmaceutical Tech Co Ltd Jak-inhibiittoriyhdiste ja sen käyttö
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途

Also Published As

Publication number Publication date
WO2020051139A1 (en) 2020-03-12
KR20210056380A (ko) 2021-05-18
UA127328C2 (uk) 2023-07-19
ZA202100990B (en) 2024-09-25
JP2021535174A (ja) 2021-12-16
EA202190686A1 (ru) 2021-07-23
EP3837010A1 (en) 2021-06-23
CN112703037A (zh) 2021-04-23
EP3837010B1 (en) 2023-07-05
SG11202101751XA (en) 2021-03-30
CO2021002976A2 (es) 2021-05-31
CN112703037B (zh) 2023-10-20
IL281150B2 (en) 2024-03-01
ES2955717T3 (es) 2023-12-05
PH12021550324A1 (en) 2021-10-04
TW202024075A (zh) 2020-07-01
BR112021004063A2 (pt) 2021-05-25
US11713315B2 (en) 2023-08-01
US10836763B2 (en) 2020-11-17
JP7383696B2 (ja) 2023-11-20
TWI793365B (zh) 2023-02-21
IL281150B1 (en) 2023-11-01
IL281150A (en) 2021-04-29
US20200071325A1 (en) 2020-03-05
US20210024517A1 (en) 2021-01-28
AR116114A1 (es) 2021-03-31
AU2019335200A1 (en) 2021-03-11
EP3837010C0 (en) 2023-07-05
CL2021000515A1 (es) 2021-07-23

Similar Documents

Publication Publication Date Title
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
PH12021550368A1 (en) Dimethyl amino azetidine amides as jak inhibitors
ZA201802496B (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
GEP20207202B (en) Tyrosine amide derivatives as rho-kinase inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MY199220A (en) Heterocyclic compounds as immunomodulators
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
MY199446A (en) Compounds and compositions and uses thereof
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
NZ762437A (en) Novel heterocyclic compounds as cdk8/19 inhibitors
NZ737536A (en) Substituted benzamides and methods of use thereof
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
MX385475B (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена